Richard E. Lowenthal - 19 Apr 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
19 Apr 2024
Net transactions value
+$199,999
Form type
4
Filing time
22 Apr 2024, 19:22:25 UTC
Previous filing
17 Apr 2024
Next filing
24 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $99,999 +119,047 +2.9% $0.8400* 4,245,869 19 Apr 2024 Direct
transaction SPRY Common Stock Options Exercise $99,999 +69,444 +1.6% $1.44 4,315,313 19 Apr 2024 Direct
holding SPRY Common Stock 3,276,854 19 Apr 2024 By Spouse
holding SPRY Common Stock 1,646,494 19 Apr 2024 By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 F1
holding SPRY Common Stock 1,848,499 19 Apr 2024 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 F2
holding SPRY Common Stock 1,647,447 19 Apr 2024 By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Options Exercise $0 -119,047 -50% $0.000000 117,333 19 Apr 2024 Common Stock 119,047 $0.8400 Direct F4
transaction SPRY Stock Option (right to buy) Options Exercise $0 -69,444 -29% $0.000000 166,936 19 Apr 2024 Common Stock 69,444 $1.44 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is trustee of the trust.
F2 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
F3 The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.